Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...
In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...
In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication in 'The Journal of Medical Economics' of a novel health economics methodology used to develop the cost-utility model ...
FOX CHASE, Pa. -- Bladder cancer is one of the most common cancers - just behind melanoma. Yet, many people don't know much about it. Doctors are now using a diagnostic tool to better find and ...
Dr. David Greenberg outlines bladder cancer staging, BCG, immunotherapy, surgery, quality of life impacts and long-term ...
Bladder cancer affects approximately 83,000 Americans each year, yet remains one of the most overlooked forms of cancer despite having excellent survival rates when caught early. This disconnect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results